newsfilter
← Latest News
ACCESS Newswire·

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

  • Protagonist Therapeutics President & CEO Dinesh V. Patel will participate in two investment bank conferences in June 2026.
  • The 2026 Jefferies Global Healthcare Conference fireside chat is scheduled for Wednesday, June 3 at 9:55 A.M. ET in New York, NY.
  • The Goldman Sachs 47th Annual Global Healthcare Conference 2026 fireside chat is scheduled for Wednesday, June 10 at 9:20 A.M. ET in Miami, FL.
  • Webcasts are available for both events via provided links.
  • ICOTYDE™ (icotrokinra), a targeted oral peptide licensed to Janssen Biotech, Inc., launched in the U.S. in March 2026 for moderate-to-severe plaque psoriasis in adults & pediatric patients 12 years or older.
  • ICOTYDE is in Phase 3 development for psoriatic arthritis, ulcerative colitis, & Crohn's disease.
  • An NDA for rusfertide, a hepcidin mimetic peptide licensed to Takeda Pharmaceuticals, is under priority review with the FDA for polycythemia vera.
  • Protagonist's pipeline includes an oral IL-17 antagonist peptide, obesity dual & triple agonists, an oral hepcidin functional mimetic, & recently announced IL-4 & amylin programs.
  • Replays of the presentations will be available on the Company's Investor Relations webpage for one year following the events.